The fight against dengue fever in Malaysia takes a significant leap forward with the introduction of Takeda’s Qdenga® (Dengue Tetravalent Vaccine [Live, Attenuated]). This innovative vaccine, recently approved by the Drug Control Authority (DCA) Malaysia, offers protection against all four dengue virus serotypes for individuals aged four years and above. It is now available in most private hospitals and clinics across the country.
Qdenga® is notable for its ability to provide broad protection without requiring pre-vaccination testing, making it accessible to a wider population. Clinical trials have demonstrated its impressive efficacy, showing 80.2% overall protection against dengue after 12 months and 90.4% protection against hospitalization after 18 months.
